GLPBio

Stachyose

Catalog No.: GC18245Purity:>80.00%
COASDSData Sheet
Stachyose is an oligosaccharide and prebiotic.

Products are for research use only. Not for human use. We do not sell to patients.

Stachyose
Cas No.: 470-55-3
1gIn Stock
$60.00
1
5gIn Stock
$180.00
1
25gIn Stock
$780.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Stachyose is an oligosaccharide and prebiotic[1]. Stachyose also serves as a specific inhibitor of PRDX5 (peroxiredoxin 5), acts directly on the PRDX5 protein, and inhibits its enzymatic activity[2]. Stachyose is commonly used in research on castration-resistant prostate cancer and metabolic diseases such as type 2 diabetes[3][4].

In vitro, Stachyose (0.4-3.2mg/mL in medium; 24h) dose-dependently inhibited Caco-2 colon cancer cells proliferation, induced cells apoptosis, decreased mitochondrial membrane potential, upregulated Bax, downregulated Bcl-2, promoted cytochrome C release, and activated caspases 3/9[5].

In vivo, Stachyose (200-600mg/kg/day; oral gavage for 3 weeks) dose-dependently alleviated DSS-induced colitis symptoms, increased tight junction protein expression (Occludin, Claudin-1, ZO-1), decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), increased anti-inflammatory cytokine IL-10, and restored Treg/Th17 cell balance in a DSS-induced colitis mouse model[6]. Stachyose (1 or 5g/kg/day; oral gavage for 3 days) reduced myocardial infarction area and improved cardiac function in a mouse model of myocardial ischemia-reperfusion injury[7].

References:
[1] Li CN, Wang X, Lei L, et al. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice. Phytother Res. 2020;34(5):1166-1174.
[2] Wang R, Pan Y, Zhang L, et al. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024;278(Pt 3):134844.
[3] Wang R, Mi Y, Ni J, et al. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2024;11(9):e2304939.
[4] Wu Y, Cao Y, Feng L, et al. The natural compound stachyose targets SGLT2-mediated metabolic reprogramming to ameliorate diabetic kidney disease. Phytomedicine. 2025;147:157182.
[5] Huang G, Mao J, Ji Z, Ailati A. Stachyose-induced apoptosis of Caco-2 cells via the caspase-dependent mitochondrial pathway. Food Funct. 2015;6(3):765-771.
[6] He N, Chen K, Yu S, et al. Stachyose Exerts Anticolitis Efficacy by Re-balancing Treg/Th17 and Activating the Butyrate-Derived PPARγ Signaling Pathway. J Agric Food Chem. 2024;72(21):12171-12183.
[7] Zhang AY, Su JB, Sun HT, et al. Stachyose ameliorates myocardial ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis and macrophage pyroptosis. Int Immunopharmacol. 2024;143(Pt 1):113334.

Protocol

Cell experiment [1]:

Cell lines

Caco-2 cells

Preparation Method

Caco-2 cells from passages 30 to 50 were used in this experiment. After reaching subconfluence, Caco-2 cells were recovered from the culture flask through 0.25% trypsin digestion after washing twice with PBS. The medium was changed every 2d. Cell counts based on conductivity measurements and cell viability were assessed using the trypan blue test. To evaluate the cytotoxic effect of Stachyose, cells in the log phase were seeded in 96-well cell culture plates (104 cells per well) and pre-incubated for 24h. The cells were then treated with Serum free medium (SFM) mixed with different Stachyose concentrations (0, 0.4, 0.8, 1.6, 3.2mg/mL) for 24h. The MTT assay was used to measure cell viability according to the commercially available protocol. Flow cytometry analysis for cell apoptosis was performed by using an annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit.

Reaction Conditions

0.4-3.2mg/mL; 24h

Applications

Stachyose dose-dependently inhibited Caco-2 colon cancer cells proliferation and induced cells apoptosis.
Animal experiment [2]:

Animal models

Male C57BL/6J mice

Preparation Method

Male C57BL/6J mice, aged 6 weeks were housed in a controlled environment with regulated humidity and temperature, and were provided free access to standard chow and clean water on a 12-h light-dark cycle. After one week acclimatization, the effects of Stachyose on a mouse model of MIRI were evaluated. Stachyose (1 or 5g/kg/day) was administered via gavage for three consecutive days before sham or MIRI surgery. The MIRI model was established under clean and standardized conditions. Echocardiography was performed using the Vevo 3100LT ultrasound cardiography system. After the echocardiography was completed, the mice were euthanized by cervical dislocation, the chest skin and ribs were incised, and the apex of the heart was rinsed with physiological saline. The hearts were then removed and frozen at -20℃ for 20min. Once the hearts were fully frozen, it was dissected using a surgical tool. The hearts were then soaked in 2,3,5-triphenyltetrazolium chloride (TTC dye) at 37℃ for 30min. The necrotic area appeared white, while the viable myocardium was red. After being incubated in 4% paraformaldehyde for 24h, the heart was photographed against a white background.

Dosage form

1 or 5g/kg/day; oral gavage for 3 days

Applications

Stachyose reduced myocardial infarction area and improved cardiac function in a mouse model of myocardial ischemia-reperfusion injury.

References:
[1] Huang G, Mao J, Ji Z, Ailati A. Stachyose-induced apoptosis of Caco-2 cells via the caspase-dependent mitochondrial pathway. Food Funct. 2015;6(3):765-771.
[2] Zhang AY, Su JB, Sun HT, et al. Stachyose ameliorates myocardial ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis and macrophage pyroptosis. Int Immunopharmacol. 2024;143(Pt 1):113334.

Product Documents

Purity:>80.00%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
470-55-3
Molecular Formula
C24H42O21
Molecular Weight
666.58
Solubility
H2O : 125 mg/mL (Need ultrasonic)
Storage
Store at RT
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Stachyose

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%